Romania

Show information for:

Information and guides

BackSavedSign in

Support / Info

Clinical trials for lymphoma in Romania

Which studies are listed as recruiting, where the centres are, and how to contact the team. Record source: ClinicalTrials.gov.

← All cancer types

How to read this list

Each card is a study listed as recruiting with a recruiting centre in Romania. Open the sections in the card to see the participant overview, study groups, calendar and all published local centres and contacts. The study team confirms eligibility and availability; the original registry record remains available for the complete protocol information.

Trials recruiting now

Every title below has been rewritten in plain language by our editorial team, with the original underneath.

Trials testing a treatment · 8 studies

Something new is being tried here: a medicine, a regimen or a procedure. If you join, you receive either the treatment under study or the standard one, and the team follows you closely.

NCT05645107Phase 3Listed as recruiting

Preventing infections in patients with low immunoglobulins: subcutaneous immunoglobulin compared with placebo

The primary purpose of the study is to evaluate whether biweekly administered XEMBIFY® plus Standard Medical Treatment (SMT) over a one-year period will reduce the rate of major bacterial infections per participant per year in B-cell CLL, MM, and NHL participants with hypogammaglobulinemia (HGG) in comparison to the Placebo plus SMT group.

Minimum age: 18 years

Centres in: Brașov · București · Cluj-Napoca · and 3 more cities

See all centres (10)

These centres appear in the record of a recruiting study. Confirm availability with the team before travelling. One centre may have several teams with different contacts.

Central study contact

To find the team and exact institution in your chosen city, quote study NCT05645107. This contact may be in another country; ask which language you can use.

Source: study registry

We could not read the directory's general contacts right now. Contacts published in the registry are shown in this card.

Brașov

București

Cluj-Napoca

Constanța

Iași

Timișoara

Who can take part

Preventing infections in patients with low immunoglobulins: subcutaneous immunoglobulin compared with placebo

The primary purpose of the study is to evaluate whether biweekly administered XEMBIFY® plus Standard Medical Treatment (SMT) over a one-year period will reduce the rate of major bacterial infections per participant per year in B-cell CLL, MM, and NHL participants with hypogammaglobulinemia (HGG) in comparison to the Placebo plus SMT group.

Minimum age:
18 years
Maximum age:
Not specified in the record consulted
Participant sex, as recorded in the registry:
All sexes

This is an overview, not confirmation of eligibility. The study team reviews your records, the inclusion and exclusion criteria and the other protocol requirements.

Criteria published in the registry — English original

Inclusion Criteria: * Participants ≥18 years of age at screening visit * Participants with documented and confirmed diagnosis of any of the below diseases: * B-cell CLL according to International Workshop on CLL (iwCLL) criteria and RAI staging of intermediate (1 and 2) or high (3 and 4) * MM according to the International Myeloma Working Group criteria (IMWG), R-ISS stage II or, III; or * Histologically confirmed diagnosis of B-Cell NHL, Stage III or above (IV, Progressive/refractory, or recurrent/relapsed stage) according to the Lugano Classification. * Participants with HGG with IgG levels less than 5 g/L. (Note: For MM subjects, the IgG level is adjusted by subtracting the M-protein \[Mspike\] to reflect the true polyclonal IgG concentration.) * Participants with documented history of at least one severe bacterial infection (bacterial or viral) or recurrent bacterial/viral infections (that is., ≥ 3 infections) within 12 months before the screening visit. Severe bacterial/viral infections ≥ Grade 3 (as defined by Common Terminology Criteria for Adverse Events \[CTCAE\] Grades). Exclusion Criteria: * Participants with documented history of hematopoietic stem cell transplant (allogenic transplant in the previous 24 months, and autologous transplant in the previous 3 months) before Screening visit. * Participants currently receiving immunoglobulin replacement therapy (IgRT) or have received IgG replacement treatment (i.e., prior immune globulin replacement therapy) within 6 months before the screening visit. * Participants with active infections at time of screening visit. Specific supportive anti-infective prophylactic defined in the CLL National Comprehensive Cancer Network (NCCN) or iwCLL guidelines and/or local/international guidelines for the CLL, and defined in local/international guidelines for MM and NHL are allowed, or recommended in the updated labelling of specific active target disease medicines used during the participation in the trial is also allowed. * Participants with active second malignancies. * Participants with known primary immunodeficiency (PI). * Participants with a life expectancy less than 1.5 years. * Participants with clinical evidence of any significant acute or chronic disease that, in the opinion of the investigator, may interfere with successful completion of the trial or place the subject at undue medical risk. * Participants have had a known serious adverse reaction (AR) to immunoglobulin or any anaphylactic reaction to blood or any blood-derived product. * Participants have a history of blistering skin disease, bleeding disorder, diffuse rash, recurrent skin infections, or other disorders where SC therapy would be contraindicated during the study based upon the Investigator's discretion. * Participants have known Selective Immunoglobulin A (IgA) Deficiency (with or without antibodies to IgA) (Note: exclusion is for the specific diagnostic entity. It does not exclude other forms of humoral primary immunodeficiency which have decreased IgA in addition to decreased IgG requiring IgG replacement). * Participants with severe known kidney disease \[as defined by estimated glomerular filtration rate \[eGFR\] less than (\<) 30 milliliter (mL)/min/1.73 square meter (m2)\] as determined by the Principal Investigator. * Participants that have liver enzyme levels (alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], gammaglutamyl transferase \[GGT\], or lactate dehydrogenase \[LDH\]) greater than 3 times the upper limit of normal (ULN) at the Screening Visit as defined by the testing laboratory. * Participants have a history (either 1 episode within the year prior to the Screening Visit or 2 previous episodes over a lifetime) of or current diagnosis of thromboembolism (example, myocardial infarction, cerebrovascular accident, or transient ischemic attack) or deep venous thrombosis. * Participants currently have a known hyperviscosity syndrome or hypercoagulable states. * Participants have a known previous infection or clinical signs and symptoms consistent with current hepatitis B virus or hepatitis C virus infection. * Participants with non-controlled arterial hypertension (systolic blood pressure \[SBP\] greater than 140 millimeters of mercury (mmHg) and/or diastolic blood pressure \[DBP\] greater than 90 mmHg), and/or a heart rate (HR) greater than100 bpm. * Participants with known substance or prescription drug abuse within 12 months before the Screening Visit. * Participants have participated in another clinical trial within 30 days prior to screening (observational studies without investigative treatments \[non-interventional\] are permitted).

What taking part involves

Participants are randomly assigned to the study groups.

These source names are associated with each group and may include alternatives or different stages. They do not imply that all are given simultaneously. The team explains the regimen, doses and schedule.

  • Group 1 · Studied intervention

    Xembify

  • Group 2 · Placebo comparison

    Placebo

Start of the whole study
26 December 2022
Completion of the whole study
August 2029 (estimated)

These are global study dates, not an individual's participation duration or an enrolment deadline.

Confirm participation duration, visit frequency and possible admissions with the centre team; they cannot be inferred from global study dates.

Ask the study team before travelling:

  • whether places are available at the chosen centre and how the first assessment is arranged
  • how often you need to attend the centre and whether a hospital stay is necessary
  • whether travel or accommodation costs are covered and under what conditions
  • which documents you need to prepare and whether a family member or carer can accompany you
Original registry title

A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma

Updated in the registry: 12 November 2026

Data consulted: 19 November 2026

See the official record ↗

If the official record does not open, you can still read the information and contacts in this card. The ClinicalTrials.gov record is in English.

NCT06588478Phase 2Listed as recruiting

Relapsed chronic lymphocytic leukaemia or small lymphocytic lymphoma: pirtobrutinib

The main purpose of Part 1 of this study is to assess the efficacy and safety of 3 dose levels of Pirtobrutinib in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), who have received 1-3 lines of treatment including a covalent Bruton tyrosine kinase (BTK) inhibitor. The purpose of Part 2 of this study is to evaluate pirtobrutinib monotherapy in participants with treatment-naïve CLL/SLL with 17p deletions. Participation in Part 1 is expected to last approximately 3 years. Participation in Part 2 is expected to last up to 2 years.

Minimum age: 18 years

Centres in: București · Cluj-Napoca · Craiova · and 2 more cities

See all centres (6)

These centres appear in the record of a recruiting study. Confirm availability with the team before travelling. One centre may have several teams with different contacts.

Central study contact

To find the team and exact institution in your chosen city, quote study NCT06588478. This contact may be in another country; ask which language you can use.

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or

1-317-615-4559 (dialling format unconfirmed)

LillyTrials@Lilly.com

Physicians interested in becoming principal investigators please contact

clinical_inquiry_hub@lilly.com

Source: study registry

We could not read the directory's general contacts right now. Contacts published in the registry are shown in this card.

București

  • Fundeni Clinical Institute

    Contact for this study

    Ana Maria Moldovianu

    Source: study registry

  • Spitalul Clinic Colțea

    Contact for this study

    Gabriela Borsaru

    Source: study registry

Cluj-Napoca

Craiova

  • Spitalul Clinic Municipal Filantropia Craiova

    Contact for this study

    Ocroteala Luminita

    Source: study registry

Iași

  • Institutul Regional de Oncologie

    Contact for this study

    Catalin Danaila

    Source: study registry

Ovidiu

  • Ovidius Clinical Hospital OCH

    Contact for this study

    Andreea Caloian

    Source: study registry

Who can take part

Relapsed chronic lymphocytic leukaemia or small lymphocytic lymphoma: pirtobrutinib

The main purpose of Part 1 of this study is to assess the efficacy and safety of 3 dose levels of Pirtobrutinib in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), who have received 1-3 lines of treatment including a covalent Bruton tyrosine kinase (BTK) inhibitor. The purpose of Part 2 of this study is to evaluate pirtobrutinib monotherapy in participants with treatment-naïve CLL/SLL with 17p deletions. Participation in Part 1 is expected to last approximately 3 years. Participation in Part 2 is expected to last up to 2 years.

Minimum age:
18 years
Maximum age:
Not specified in the record consulted
Participant sex, as recorded in the registry:
All sexes

This is an overview, not confirmation of eligibility. The study team reviews your records, the inclusion and exclusion criteria and the other protocol requirements.

Criteria published in the registry — English original

Inclusion Criteria: * Have confirmed diagnosis of CLL/SLL as defined by iwCLL 2018 criteria. * Part 1: Have received prior CLL/SLL treatment * Have received at least 1, but not more than 3 lines of prior treatment for CLL/SLL * Have received a covalent BTK inhibitor * Part 2: Have received no prior treatment for CLL/SLL * Part 1 - Known 17p deletion status (positive or negative) * Part 2 - Must have 17p deletion (positive) * Have a requirement for therapy consistent with iwCLL 2018 criteria for initiation of therapy * Capable of swallowing oral study medication. * Have an Eastern Cooperative Oncology Group Performance Status (ECOG) score of 0 to 2. Exclusion Criteria: * Have received prior treatment with a BTK degrader or a noncovalent BTK inhibitor * Have a history of greater than or equal to (\>=) Grade 3 bleeding due to treatment with a BTK inhibitor * Have known or suspected Richter's transformation * Have known or suspected history of central nervous system involvement by CLL/SLL * Previous or concurrent cancer distinct from CLL/SLL within 3 years before randomization. Exceptions may occur with documented sponsor approval. Examples include: * nonmelanoma skin cancer or lentigo malignant melanoma * cervical carcinoma in situ * localized prostate cancer undergoing active surveillance, and * localized (for example, lymph node negative) breast cancer with no evidence of active disease present for more than 3 years. Individual may be receiving adjuvant hormonal therapy

What taking part involves

Participants are randomly assigned to the study groups.

These source names are associated with each group and may include alternatives or different stages. They do not imply that all are given simultaneously. The team explains the regimen, doses and schedule.

  • Group 1 · Active treatment comparison

    Pirtobrutinib

  • Group 2 · Studied intervention

    Pirtobrutinib

  • Group 3 · Studied intervention

    Pirtobrutinib

  • Group 4 · Studied intervention

    Pirtobrutinib

Start of the whole study
3 January 2025
Completion of the whole study
December 2028 (estimated)

These are global study dates, not an individual's participation duration or an enrolment deadline.

Confirm participation duration, visit frequency and possible admissions with the centre team; they cannot be inferred from global study dates.

Ask the study team before travelling:

  • whether places are available at the chosen centre and how the first assessment is arranged
  • how often you need to attend the centre and whether a hospital stay is necessary
  • whether travel or accommodation costs are covered and under what conditions
  • which documents you need to prepare and whether a family member or carer can accompany you
Original registry title

A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Updated in the registry: 4 November 2026

Data consulted: 19 November 2026

See the official record ↗

If the official record does not open, you can still read the information and contacts in this card. The ClinicalTrials.gov record is in English.

NCT04728893Phase 2Listed as recruiting

Blood cancers: nemtabrutinib, a medicine under study

The purpose of this study is to evaluate the safety and efficacy of nemtabrutinib (formerly ARQ 531) in participants with hematologic malignancies of chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL), Richter's transformation, marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), follicular lymphoma (FL), and Waldenström's macroglobulinemia (WM).

Minimum age: 18 years

Centres in: Brașov · București · Iași

See all centres (3)

These centres appear in the record of a recruiting study. Confirm availability with the team before travelling. One centre may have several teams with different contacts.

Central study contact

To find the team and exact institution in your chosen city, quote study NCT04728893. This contact may be in another country; ask which language you can use.

Toll Free Number

1-888-577-8839 (dialling format unconfirmed)

Trialsites@msd.com

Source: study registry

We could not read the directory's general contacts right now. Contacts published in the registry are shown in this card.

Brașov

  • Centrul de Diagnostic si Tratament Oncologic Brasov

    Contact for this study

    Study Coordinator

    +40 729 075 567

    Source: study registry

București

  • Spitalul Clinic Colțea

    Contact for this study

    Study Coordinator

    +40 21 387 4100

    Source: study registry

Iași

  • Institutul Regional de Oncologie Iasi

    Contact for this study

    Study Coordinator

    +40 374 278 811

    Source: study registry

Who can take part

Blood cancers: nemtabrutinib, a medicine under study

The purpose of this study is to evaluate the safety and efficacy of nemtabrutinib (formerly ARQ 531) in participants with hematologic malignancies of chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL), Richter's transformation, marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), follicular lymphoma (FL), and Waldenström's macroglobulinemia (WM).

Minimum age:
18 years
Maximum age:
Not specified in the record consulted
Participant sex, as recorded in the registry:
All sexes

This is an overview, not confirmation of eligibility. The study team reviews your records, the inclusion and exclusion criteria and the other protocol requirements.

Criteria published in the registry — English original

Inclusion Criteria: * Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 within 7 days before C1D1 (the first dose of study treatment) * Has a life expectancy of at least 3 months, based on the investigator assessment * Has the ability to swallow and retain oral medication * Participants who are Hepatitis B surface antigen (HBsAg)-positive are eligible if they have received Hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load prior to randomization * Participants with history of Hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening * Has adequate organ function * Male participants agree to refrain from donating sperm and agree to either remain abstinent from penile-vaginal intercourse as their preferred and usual lifestyle OR agree to use contraception, during the intervention period and for at least the time required to eliminate the study intervention after last dose of study intervention * Female participants assigned female sex at birth who are not pregnant or breastfeeding are eligible to participate if not a participant of childbearing potential (POCBP), or if a POCBP they either use a contraceptive method that is highly effective OR remain abstinent from penile-vaginal intercourse as their preferred and usual lifestyle during the intervention period and for at least to eliminate study intervention after the last dose of study intervention * Participants with Human immunodeficiency virus (HIV) are eligible if they meet all of the following: the CD4 count is \>350 cells/uL at screening, the HIV viral load is below the detectable level, are on a stable ART regimen for at least 4 weeks prior to study entry, and are compliant with their ART Part 1 and Part 2 (Cohorts A to C and J) * Has a confirmed diagnosis of Chronic lymphocytic leukemia/ Small lymphocytic lymphoma (CLL/SLL) with * At least 2 lines of prior therapy (Part 1 only) * Part 2 Cohort A: CLL/SLL participants who are relapsed or refractory to prior therapy with a covalent, irreversible Bruton's tyrosine kinase inhibitor (BTKi), and a B-cell lymphoma 2 inhibitor (BCL2i). CLL participants must have received and failed, been intolerant to, or determined by their treating physician to be a poor phosphoinositide 3-kinase inhibitor (PI3Ki) candidate or ineligible for a PI3Ki per local guidelines * Part 2 Cohort B: CLL/SLL participants who are relapsed or refractory following at least 1 line of prior therapy and are BTKi treatment naive * Part 2 Cohort C: CLL/SLL participants with 17p deletion or tumor protein p53 (TP53) mutation who are relapsed or refractory following at least 1 line of prior therapy * Part 2 Cohort J: CLL/SLL participants whose disease relapsed or was refractory to prior therapy with a covalent/irreversible BTKi and BCL2i. NOTE: As of Protocol Amendment 09, at least 10 CLL/SLL participants whose disease relapsed or was refractory to prior therapy with a covalent/irreversible BTKi, BCL2i and noncovalent/reversible BTKi (all three classes of therapies are required) will be enrolled into Cohort J * Has active disease for CLL/SLL clearly documented to initiate therapy * For SLL participants in Part 2: Has evaluable core or excisional lymph node biopsy for biomarker analysis from an archival or newly obtained biopsy or bone marrow aspirate at Screening (optional for participants enrolling in Part 1) Part 2 (Cohorts D to G) \- Has a confirmed diagnosis of and meets the following prior therapy requirements: * Participants with Richter's transformation who are relapsed or refractory following at least 1 line of prior therapy (Cohort D) * Participants with pathologically confirmed Mantle-cell lymphoma (MCL), documented by either overexpression of cyclin D1 or t (11;14), who are relapsed or are refractory to chemoimmunotherapy and a covalent irreversible BTKi (Cohort E) * Participants with Marginal zone lymphoma (MZL) (including splenic, nodal, and extra nodal MZL) who are relapsed or refractory to at least one prior line of systemic therapy including an anti-CD20-based regimen * Participants with Follicular lymphoma (FL) who are relapsed or refractory to chemoimmunotherapy and immunomodulatory agents (such as lenalidomide based regimen) (Cohort G) * Have measurable disease defined as at least 1 lesion that can be accurately measured in at least 2 dimensions with spiral Computed tomography (CT) scan * Has a lymph node biopsy for biomarker analysis from an archival or newly obtained biopsy or bone marrow aspirate (Cohort D) at Screening Part 2 (Cohort H): confirmed diagnosis of Waldenström's macroglobulinemia (WM); participants who are relapsed or refractory to standard therapies for WM including chemoimmunotherapy and a covalent irreversible BTKi * Has active disease defined as 1 of the following: systemic symptoms, physical findings, laboratory abnormalities, coexisting disease * Has measurable disease, satisfying any of the following: at least 1 lesion that can be accurately measured in at least 2 dimensions with spiral CT scan (minimum measurement must be \>15 mm in the longest diameter or \>10 mm in the short axis); IgM ≥450 mg/dL; or bone marrow infiltration of 10% * Has fresh bone marrow aspirate or a lymph node biopsy for biomarker analysis at Screening or a lymph node biopsy from an archival Exclusion Criteria: * Has active HBV/HCV infection (Part 1 and Part 2) * Has a history of malignancy ≤3 years before providing documented informed consent. Participants with basal cell carcinoma of skin, squamous cell carcinoma of skin, or carcinoma in situ (e.g., breast carcinoma, cervical cancer in situ) that have undergone potential curative therapy are not excluded. Participants with low-risk, early-stage prostate cancer (T1-T2a, Gleason score ≤6, and prostate-specific antigen \<10 ng/mL) either treated with definitive intent or untreated in active surveillance with SD are not excluded * Has active central nervous system (CNS) disease * Has an active infection requiring systemic therapy * Has received prior systemic anti-cancer therapy within 5 half-lives or 4 weeks (if prior therapy was a monoclonal antibody) before C1D1 * Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study intervention * Has any clinically significant gastrointestinal abnormalities that might alter absorption * History of severe bleeding disorders

What taking part involves

The record does not specify how participants are assigned to groups.

These source names are associated with each group and may include alternatives or different stages. They do not imply that all are given simultaneously. The team explains the regimen, doses and schedule.

  • Group 1 · Studied intervention

    Nemtabrutinib

Start of the whole study
5 April 2021
Completion of the whole study
4 January 2029 (estimated)

These are global study dates, not an individual's participation duration or an enrolment deadline.

Confirm participation duration, visit frequency and possible admissions with the centre team; they cannot be inferred from global study dates.

Ask the study team before travelling:

  • whether places are available at the chosen centre and how the first assessment is arranged
  • how often you need to attend the centre and whether a hospital stay is necessary
  • whether travel or accommodation costs are covered and under what conditions
  • which documents you need to prepare and whether a family member or carer can accompany you
Original registry title

Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)

Updated in the registry: 17 November 2026

Data consulted: 19 November 2026

See the official record ↗

If the official record does not open, you can still read the information and contacts in this card. The ClinicalTrials.gov record is in English.

NCT06104566Phase 3Listed as recruiting

Chronic lymphocytic leukaemia or small lymphocytic lymphoma: APG2575, a medicine under study

This is a global multicenter, open label, randomized, registrational phase III study to investigate the efficacy and safety of lisaftoclax in combination with BTK inhibitors in CLL/SLL patients who previously treated with BTK inhibitors

Minimum age: 18 years

Centres in: București · Cluj-Napoca · Timișoara

See all centres (3)

These centres appear in the record of a recruiting study. Confirm availability with the team before travelling. One centre may have several teams with different contacts.

Central study contact

To find the team and exact institution in your chosen city, quote study NCT06104566. This contact may be in another country; ask which language you can use.

Shanthi Marur, MD

3017925062 (dialling format unconfirmed)

shanthi.marur@ascentage.com

Yifan Zhai, MD

301-549-6188 (dialling format unconfirmed)

yzhai@ascentage.com

Source: study registry

We could not read the directory's general contacts right now. Contacts published in the registry are shown in this card.

București

Cluj-Napoca

Timișoara

Who can take part

Chronic lymphocytic leukaemia or small lymphocytic lymphoma: APG2575, a medicine under study

This is a global multicenter, open label, randomized, registrational phase III study to investigate the efficacy and safety of lisaftoclax in combination with BTK inhibitors in CLL/SLL patients who previously treated with BTK inhibitors

Minimum age:
18 years
Maximum age:
99 years
Participant sex, as recorded in the registry:
All sexes

This is an overview, not confirmation of eligibility. The study team reviews your records, the inclusion and exclusion criteria and the other protocol requirements.

Criteria published in the registry — English original

Inclusion Criteria: 1. Age ≥ 18 years. 2. Patients that have documented CLL/SLL who meet iwCLL 2018 criteria for CLL treatment guidelines are eligible for treatment and must be receiving BTKi monotherapy for at least 12 months 3. ECOG Performance Status grade 0-2 4. Adequate bone marrow function independent of growth factor or transfusion support within 2 weeks of screening initiation as follows: * Absolute neutrophil count ≥ 1.0 × 109/L * Platelet counts ≥ 75 × 109/L; in cases of thrombocytopenia * Total hemoglobin ≥ 9 g/dL, 5. Adequate renal function * Creatinine clearance must be \> 50 ml/min directly measured with 24hr urine collection or calculated according to the modified formula of Cockcroft and Gault (for men: GFR ≈ ((140 - age) x actual body weight)/(72 x creatinine), for women x 0.85) or an equally accurate method. * For patients with creatinine values within the normal range, the calculation of clearance is not necessary. Dehydrated patients with an estimated creatinine clearance less than 50 ml/min may be eligible if a repeat estimate after adequate hydration is \> 50 ml/min. 6. Adequate liver function as indicated by: * Total bilirubin ≤ 1.5 x ULN, except patients with known Gilbert's Syndrome * Aspartate aminotransferase (AST) ≤ 2.5 x the institutional ULN value * Alanine aminotransferase (ALT) ≤ 2.5 x the institutional ULN value, * International normalized Ratio (INR), Prothrombin Time (PT) or Activated Partial Thromboplastin time (APTT) ≤ 1.5×ULN. 7. Ability and willingness to provide written informed consent and to adhere to the study visit schedule and other protocol requirements

What taking part involves

Participants are randomly assigned to the study groups.

These source names are associated with each group and may include alternatives or different stages. They do not imply that all are given simultaneously. The team explains the regimen, doses and schedule.

  • Group 1 · Active treatment comparison

    lisaftoclax +BTK inhibitor

  • Group 2 · Active treatment comparison

    BTK inhibitor

Start of the whole study
20 December 2023
Completion of the whole study
31 October 2027 (estimated)

These are global study dates, not an individual's participation duration or an enrolment deadline.

Confirm participation duration, visit frequency and possible admissions with the centre team; they cannot be inferred from global study dates.

Ask the study team before travelling:

  • whether places are available at the chosen centre and how the first assessment is arranged
  • how often you need to attend the centre and whether a hospital stay is necessary
  • whether travel or accommodation costs are covered and under what conditions
  • which documents you need to prepare and whether a family member or carer can accompany you
Original registry title

Global Trial in APG2575 for Patients With CLL/SLL

Updated in the registry: 18 June 2026

Data consulted: 19 November 2026

See the official record ↗

If the official record does not open, you can still read the information and contacts in this card. The ClinicalTrials.gov record is in English.

NCT06717347Phase 3Listed as recruiting

Untreated diffuse large B-cell lymphoma: zilovertamab vedotin replacing vincristine in the classic regimen

The purpose of this study is to evaluate if zilovertamab vedotin with standard treatment can help people live longer without the cancer growing or spreading than people who receive standard treatment alone.

Minimum age: 18 years

Centres in: Brașov · Cluj-Napoca · Sibiu

See all centres (3)

These centres appear in the record of a recruiting study. Confirm availability with the team before travelling. One centre may have several teams with different contacts.

Central study contact

To find the team and exact institution in your chosen city, quote study NCT06717347. This contact may be in another country; ask which language you can use.

Toll Free Number

1-888-577-8839 (dialling format unconfirmed)

Trialsites@msd.com

Source: study registry

We could not read the directory's general contacts right now. Contacts published in the registry are shown in this card.

Brașov

  • Centrul de Diagnostic si Tratament Oncologic Brasov

    Contact for this study

    Study Coordinator

    +40 268 960

    Source: study registry

Cluj-Napoca

  • Institutul Oncologic Cluj

    Contact for this study

    Study Coordinator

    +40 264 598 362

    Source: study registry

Sibiu

  • Spital Judetean Sibiu

    Contact for this study

    Study Coordinator

    +40 269 215 050

    Source: study registry

Who can take part

Untreated diffuse large B-cell lymphoma: zilovertamab vedotin replacing vincristine in the classic regimen

The purpose of this study is to evaluate if zilovertamab vedotin with standard treatment can help people live longer without the cancer growing or spreading than people who receive standard treatment alone.

Minimum age:
18 years
Maximum age:
Not specified in the record consulted
Participant sex, as recorded in the registry:
All sexes

This is an overview, not confirmation of eligibility. The study team reviews your records, the inclusion and exclusion criteria and the other protocol requirements.

Criteria published in the registry — English original

Inclusion Criteria: * Has histologically confirmed diagnosis of diffuse large B-cell lymphoma (DLBCL), by prior biopsy, based on local testing according to the WHO classification of neoplasms of the hematopoietic and lymphoid tissues * Has positron emission tomography (PET) positive disease at screening, defined as 4 to 5 on the Lugano 5-point scale * Has received no prior treatment for their DLBCL * Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 assessed within 7 days before randomization * Has an ejection fraction ≥45% as determined by either echocardiogram (ECHO) or multigated acquisition (MUGA) * Human immunodeficiency virus (HIV) infected participants must have well controlled HIV on antiretroviral therapy (ART) * Who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy and have undetectable HBV viral load prior to randomization * Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening Exclusion Criteria: * Has a history of transformation of indolent disease to DLBCL * Has received a diagnosis of primary mediastinal B-cell lymphoma (PMBCL) or Grey zone lymphoma * Has Ann Arbor Stage I DLBCL * Has clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (\<6 months prior to enrollment), myocardial infarction (\<6 months prior to enrollment), unstable angina, congestive heart failure (New York Heart Association Classification Class ≥II), or serious cardiac arrhythmia requiring medication * Has clinically significant pericardial or pleural effusion * Has ongoing Grade \>1 peripheral neuropathy * Has a demyelinating form of Charcot-Marie-Tooth disease * HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease * Has ongoing corticosteroid therapy * Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed * Known additional malignancy that is progressing or has required active treatment within the past 2 years * Known active central nervous system (CNS) lymphoma * Has active autoimmune disease that has required systemic treatment in the past 2 years * Has active infection requiring systemic therapy * Has concurrent active HBV (defined as HBsAg positive and detectable HBV DNA) and HCV (defined as anti-HCV antibody positive and detectable HCV ribonucleic acid (RNA)) infection * Has history of allogeneic tissue/solid organ transplant

What taking part involves

Participants are randomly assigned to the study groups.

These source names are associated with each group and may include alternatives or different stages. They do not imply that all are given simultaneously. The team explains the regimen, doses and schedule.

  • Group 1 · Studied intervention

    Zilovertamab vedotin · Rituximab · Cyclophosphamide · Doxorubicin · Rituximab Biosimilar · Prednisone · Prednisolone · Rescue medication · Methylprednisolone

  • Group 2 · Active treatment comparison

    Rituximab · Cyclophosphamide · Doxorubicin · Rituximab Biosimilar · Prednisone · Prednisolone · Vincristine · Methylprednisolone

Start of the whole study
27 January 2025
Completion of the whole study
29 March 2032 (estimated)

These are global study dates, not an individual's participation duration or an enrolment deadline.

Confirm participation duration, visit frequency and possible admissions with the centre team; they cannot be inferred from global study dates.

Ask the study team before travelling:

  • whether places are available at the chosen centre and how the first assessment is arranged
  • how often you need to attend the centre and whether a hospital stay is necessary
  • whether travel or accommodation costs are covered and under what conditions
  • which documents you need to prepare and whether a family member or carer can accompany you
Original registry title

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

Updated in the registry: 13 November 2026

Data consulted: 19 November 2026

See the official record ↗

If the official record does not open, you can still read the information and contacts in this card. The ClinicalTrials.gov record is in English.

NCT06973187Phase 3Listed as recruiting

Relapsed chronic lymphocytic leukaemia or small lymphocytic lymphoma: BGB-16673 compared with pirtobrutinib

The purpose of this study is to evaluate the efficacy and safety of tacabrutideg alone compared with pirtobrutinib in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had been previously treated with a covalent Bruton tyrosine kinase inhibitor (cBTKi).

Minimum age: 18 years

Centres in: București · ClujNapoca · Iași

See all centres (3)

These centres appear in the record of a recruiting study. Confirm availability with the team before travelling. One centre may have several teams with different contacts.

Central study contact

To find the team and exact institution in your chosen city, quote study NCT06973187. This contact may be in another country; ask which language you can use.

Study Director

1-877-828-5568 (dialling format unconfirmed)

clinicaltrials@beonemed.com

Source: study registry

We could not read the directory's general contacts right now. Contacts published in the registry are shown in this card.

București

ClujNapoca

Iași

Who can take part

Relapsed chronic lymphocytic leukaemia or small lymphocytic lymphoma: BGB-16673 compared with pirtobrutinib

The purpose of this study is to evaluate the efficacy and safety of tacabrutideg alone compared with pirtobrutinib in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had been previously treated with a covalent Bruton tyrosine kinase inhibitor (cBTKi).

Minimum age:
18 years
Maximum age:
Not specified in the record consulted
Participant sex, as recorded in the registry:
All sexes

This is an overview, not confirmation of eligibility. The study team reviews your records, the inclusion and exclusion criteria and the other protocol requirements.

Criteria published in the registry — English original

Inclusion Criteria: * Confirmed diagnosis of CLL or SLL, requiring treatment, based on 2018 iwCLL criteria * Previously received treatment for CLL/SLL with a covalent Bruton tyrosine kinase inhibitor (cBTKi). Patients should have disease relapsed after or refractory to at least 1 line of therapy including a cBTKi. * Participants with SLL must have measurable disease by computed tomography/magnetic resonance imaging, defined as ≥ 1 lymph node \> 1.5 cm in longest diameter and measurable in 2 perpendicular diameters. Exclusion Criteria: * Known prolymphocytic leukemia or history of, or currently suspected, Richter's transformation. * History of known bleeding disorder such as hemophilia A, hemophilia B, von Willebrand disease, or history of spontaneous bleeding requiring blood transfusion or other medical intervention * History of ischemic stroke or intracranial hemorrhage within 6 months before first dose of study drug * Prior exposure to any Bruton tyrosine kinase (BTK) protein degraders or noncovalent Bruton tyrosine kinase inhibitor (ncBTKi). * Current or history of central nervous system involvement including the brain, spinal cord, leptomeninges, and cerebrospinal fluid (as documented by imaging, cytology, or biopsy) by CLL/SLL NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

What taking part involves

Participants are randomly assigned to the study groups.

These source names are associated with each group and may include alternatives or different stages. They do not imply that all are given simultaneously. The team explains the regimen, doses and schedule.

  • Group 1 · Studied intervention

    Tacabrutideg

  • Group 2 · Active treatment comparison

    Pirtobrutinib

Start of the whole study
4 September 2025
Completion of the whole study
17 April 2028 (estimated)

These are global study dates, not an individual's participation duration or an enrolment deadline.

Confirm participation duration, visit frequency and possible admissions with the centre team; they cannot be inferred from global study dates.

Ask the study team before travelling:

  • whether places are available at the chosen centre and how the first assessment is arranged
  • how often you need to attend the centre and whether a hospital stay is necessary
  • whether travel or accommodation costs are covered and under what conditions
  • which documents you need to prepare and whether a family member or carer can accompany you
Original registry title

A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Updated in the registry: 28 September 2026

Data consulted: 19 November 2026

See the official record ↗

If the official record does not open, you can still read the information and contacts in this card. The ClinicalTrials.gov record is in English.

NCT04920617Phase 2Listed as recruiting

Relapsed or refractory diffuse large B-cell lymphoma: a therapeutic vaccine alongside pembrolizumab

This is a Phase 2b, randomized, open label study to assess the safety and efficacy of DPX-Survivac and pembrolizumab, with and without low-dose cyclophosphamide (CPA) in subjects with relapsed or refractory DLBCL.

Minimum age: 18 years

Centres in: București · Cluj-Napoca

See all centres (2)

These centres appear in the record of a recruiting study. Confirm availability with the team before travelling. One centre may have several teams with different contacts.

We could not read the directory's general contacts right now. Contacts published in the registry are shown in this card.

București

Cluj-Napoca

Who can take part

Relapsed or refractory diffuse large B-cell lymphoma: a therapeutic vaccine alongside pembrolizumab

This is a Phase 2b, randomized, open label study to assess the safety and efficacy of DPX-Survivac and pembrolizumab, with and without low-dose cyclophosphamide (CPA) in subjects with relapsed or refractory DLBCL.

Minimum age:
18 years
Maximum age:
Not specified in the record consulted
Participant sex, as recorded in the registry:
All sexes

This is an overview, not confirmation of eligibility. The study team reviews your records, the inclusion and exclusion criteria and the other protocol requirements.

Criteria published in the registry — English original

Key Inclusion Criteria: * Adults ≥ 18 years of age who are willing and able to provide written informed consent * Have an ECOG performance status of ≤ 1. Subjects with an ECOG performance status of 2 may be enrolled with Medical Monitor approval. * Pathologically confirmed diagnosis of DLBCL, as defined by the 2016 World Health Organization classification including DLBCL NOS high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements, Epstein-barr virus (EBV) positive DLBCL, and T cell rich B cell lymphoma (TCRBCL). Subjects with DLBCL transformed from indolent lymphoma (except for Richter's transformation) are eligible. * Subjects must have progressive disease following at least two (2) lines of prior systemic therapy for DLBCL; prior treatment must have included an anthracycline and rituximab (or another CD20-targeted agent). * Subjects must have failed or be ineligible for ASCT or CAR-T * Have at least one bi-dimensionally measurable lesion per Lugano (2014) * Willing to provide pre-treatment and on-treatment tumor biopsy tissue. * Meet protocol-specified laboratory requirements * Life expectancy \> 3 months. Key Exclusion Criteria: * Primary CNS lymphoma or active secondary CNS involvement and/or lymphomatous meningitis * Chemotherapy, immunotherapy, major surgery, or investigational agent treatment within 28 days of D0 or 5 half-lives, whichever is shorter * Radiotherapy within 14 days of day 0 * Autologous stem cell transplant (ASCT) within ˂100 days prior to D0 * Chimeric antigen receptor T cell (CAR-T) therapy within ˂28 days prior to D0 * Diagnosis of immunodeficiency disorder or history of active autoimmune disease that has required systemic treatment in the past 2 years * Uncontrolled significant active infections (controlled Hepatitis B, Hepatitis C, or HIV may be eligible) * Prior history of malignancy other than eligible lymphoma sub-types, unless the subject has been free of the disease for ≥ 2 years prior to the start of study treatment

What taking part involves

Participants are randomly assigned to the study groups.

These source names are associated with each group and may include alternatives or different stages. They do not imply that all are given simultaneously. The team explains the regimen, doses and schedule.

  • Group 1 · Studied intervention

    DPX-Survivac · Pembrolizumab · CPA

  • Group 2 · Studied intervention

    DPX-Survivac · Pembrolizumab

Start of the whole study
18 June 2021
Completion of the whole study
April 2025 (estimated)

These are global study dates, not an individual's participation duration or an enrolment deadline.

Confirm participation duration, visit frequency and possible admissions with the centre team; they cannot be inferred from global study dates.

Ask the study team before travelling:

  • whether places are available at the chosen centre and how the first assessment is arranged
  • how often you need to attend the centre and whether a hospital stay is necessary
  • whether travel or accommodation costs are covered and under what conditions
  • which documents you need to prepare and whether a family member or carer can accompany you
Original registry title

DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Updated in the registry: 7 April 2023

Data consulted: 19 November 2026

See the official record ↗

If the official record does not open, you can still read the information and contacts in this card. The ClinicalTrials.gov record is in English.

NCT05544019Phase 1Listed as recruiting

Mature B-cell cancers: SGR-1505, a medicine under study

The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or recommended dose (RD) of SGR-1505.

Minimum age: 18 years

Centres in: București · Cluj-Napoca

See all centres (2)

These centres appear in the record of a recruiting study. Confirm availability with the team before travelling. One centre may have several teams with different contacts.

Central study contact

To find the team and exact institution in your chosen city, quote study NCT05544019. This contact may be in another country; ask which language you can use.

Source: study registry

We could not read the directory's general contacts right now. Contacts published in the registry are shown in this card.

București

Cluj-Napoca

Who can take part

Mature B-cell cancers: SGR-1505, a medicine under study

The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or recommended dose (RD) of SGR-1505.

Minimum age:
18 years
Maximum age:
Not specified in the record consulted
Participant sex, as recorded in the registry:
All sexes

This is an overview, not confirmation of eligibility. The study team reviews your records, the inclusion and exclusion criteria and the other protocol requirements.

Criteria published in the registry — English original

Inclusion Criteria: * Subject must have a history of histologically or cytologically confirmed mature B-cell malignancy. * Subject must have measurable or detectable disease according to the applicable disease-specific classification system and meet criteria for initiation of treatment. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Life expectancy ≥ 12 weeks. Exclusion Criteria: * The subject is in need of immediate cytoreductive therapy (unless the patient has no remaining treatment choice with potential benefit). * Subject has previous invasive malignancy in the last 2 years. * Subject has a known allergy to SGR-1505 or excipients of SGR-1505. * Subject has symptomatic or active CNS involvement of disease. * Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding that would place the participant at increased risk to the use of an investigational drug.

What taking part involves

Group assignment is not random. The team explains the assignment specified in the protocol.

These source names are associated with each group and may include alternatives or different stages. They do not imply that all are given simultaneously. The team explains the regimen, doses and schedule.

  • Group 1 · Studied intervention

    SGR-1505

Start of the whole study
10 April 2023
Completion of the whole study
November 2027 (estimated)

These are global study dates, not an individual's participation duration or an enrolment deadline.

Confirm participation duration, visit frequency and possible admissions with the centre team; they cannot be inferred from global study dates.

Ask the study team before travelling:

  • whether places are available at the chosen centre and how the first assessment is arranged
  • how often you need to attend the centre and whether a hospital stay is necessary
  • whether travel or accommodation costs are covered and under what conditions
  • which documents you need to prepare and whether a family member or carer can accompany you
Original registry title

Study of SGR-1505 in Mature B-Cell Neoplasms

Updated in the registry: 13 February 2026

Data consulted: 19 November 2026

See the official record ↗

If the official record does not open, you can still read the information and contacts in this card. The ClinicalTrials.gov record is in English.

Observational studies · one study

You do NOT receive a new treatment here. You have your usual care, and researchers collect information about how it goes. Useful for people after you, but it does not change your own care.

NCT03964480Listed as recruiting

Observational registry for newly diagnosed peripheral T-cell lymphoma

This study T-Cell Project 2.0 is based on the former International PTCL study designed by the International T-cell Non-Hodgkin's Lymphoma Study Group (T-Cell Project 1.0: Prospective Collection of Data in Patients With Peripheral T-Cell Lymphoma) as a prospective collection of data to predict the prognosis of patients with the more frequent subtypes of PTCL. It is a prospective, longitudinal, international, observational study of patients with newly diagnosed peripheral T-cell lymphoma aiming to verify whether this prospective collection of data would allow achieving a more accurate information on T-cell lymphomas. The study aims to better define the clinical relevance of the new WHO Classification, the role of FDG-PET in staging and response assessment, the prognosis of different entities, the genomic landscape of different subtypes, and to investigate on most optimal treatment strategies for these neoplasms in the real-world population as well as molecular markers and to explore the prognostic or predictive implications of them in PTCL. The study aims to better define the clinical relevance of the new WHO Classification, the role of FDG-PET in staging and response assessment, the prognosis of different entities, the genomic landscape of different subtypes, and to investigate on most optimal treatment strategies for these neoplasms in the real-world population.

Minimum age: 18 years

Centres in: Cluj-Napoca

See all centres (1)

These centres appear in the record of a recruiting study. Confirm availability with the team before travelling. One centre may have several teams with different contacts.

Central study contact

To find the team and exact institution in your chosen city, quote study NCT03964480. This contact may be in another country; ask which language you can use.

Source: study registry

We could not read the directory's general contacts right now. Contacts published in the registry are shown in this card.

Cluj-Napoca

Who can take part

Observational registry for newly diagnosed peripheral T-cell lymphoma

This study T-Cell Project 2.0 is based on the former International PTCL study designed by the International T-cell Non-Hodgkin's Lymphoma Study Group (T-Cell Project 1.0: Prospective Collection of Data in Patients With Peripheral T-Cell Lymphoma) as a prospective collection of data to predict the prognosis of patients with the more frequent subtypes of PTCL. It is a prospective, longitudinal, international, observational study of patients with newly diagnosed peripheral T-cell lymphoma aiming to verify whether this prospective collection of data would allow achieving a more accurate information on T-cell lymphomas. The study aims to better define the clinical relevance of the new WHO Classification, the role of FDG-PET in staging and response assessment, the prognosis of different entities, the genomic landscape of different subtypes, and to investigate on most optimal treatment strategies for these neoplasms in the real-world population as well as molecular markers and to explore the prognostic or predictive implications of them in PTCL. The study aims to better define the clinical relevance of the new WHO Classification, the role of FDG-PET in staging and response assessment, the prognosis of different entities, the genomic landscape of different subtypes, and to investigate on most optimal treatment strategies for these neoplasms in the real-world population.

Minimum age:
18 years
Maximum age:
Not specified in the record consulted
Participant sex, as recorded in the registry:
All sexes

This is an overview, not confirmation of eligibility. The study team reviews your records, the inclusion and exclusion criteria and the other protocol requirements.

Criteria published in the registry — English original

Inclusion Criteria: 1. Previously-untreated patients with de novo diagnosis of peripheral T-cell or NK/T-cell lymphoma: * T-cell large granular lymphocytic leukaemia; * Chronic lymphoproliferative disorder of NK cells; * Aggressive NK-cell leukaemia; * Adult T-cell leukaemia/lymphoma; * Extranodal NK/T-cell lymphoma, nasal type; * Intestinal T-cell lymphoma; * Hepatosplenic T-cell lymphoma; * Subcutaneous panniculitis-like T-cell lymphoma; * Peripheral T-cell lymphoma, not otherwise specified; * Angioimmunoblastic T-cell lymphoma and other nodal lymphomas of T follicular helper cell origin; * Anaplastic large cell lymphoma, ALK-positive; * Anaplastic large cell lymphoma, ALK-negative; * Breast implant-associated anaplastic large cell lymphoma. 2. Age 18 and over; 3. Tissue biopsy adequate for diagnosis and classification and available for centralized review; 4. Clinical data including baseline information on disease localization and laboratory parameters at staging, features of treatment adopted and assurance of follow-up updating for at least 2 years are requested; 5. Written informed consent. Exclusion Criteria: 1. Diagnosis of: * EBV-positive T-cell and NK-cell lymphoproliferative diseases of childhood * Mycosis fungoides; * Sézary syndrome; * Primary cutaneous CD30-positive T-cell lymphoproliferative disorders; * Primary cutaneous peripheral T-cell lymphomas, rare subtypes; * T-cell lymphoblastic lymphoma/leukemia * T-cell prolymphocitic leukemia 2. Age \< 18.

What taking part involves

The record does not specify how participants are assigned to groups.

Groups or procedures are not described in enough detail in the record. Ask the study team about participation.

Start of the whole study
14 October 2018
Completion of the whole study
30 December 2027 (estimated)

These are global study dates, not an individual's participation duration or an enrolment deadline.

Confirm participation duration, visit frequency and possible admissions with the centre team; they cannot be inferred from global study dates.

Ask the study team before travelling:

  • whether places are available at the chosen centre and how the first assessment is arranged
  • how often you need to attend the centre and whether a hospital stay is necessary
  • whether travel or accommodation costs are covered and under what conditions
  • which documents you need to prepare and whether a family member or carer can accompany you
Original registry title

Prospective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma.

Updated in the registry: 16 November 2026

Data consulted: 19 November 2026

See the official record ↗

If the official record does not open, you can still read the information and contacts in this card. The ClinicalTrials.gov record is in English.

Source: ClinicalTrials.gov, the public registry of the US National Library of Medicine. Data retrieved on 19 Nov 2026.

Worth reading before you talk to your doctor

Material from our library to help you prepare your questions.

Where the official information lives

View the records in the official registries.

Where the data on this page comes from

The counts come from ClinicalTrials.gov and reflect trials marked in the registry as recruiting that also have at least one site in Romania marked as recruiting. We show cities, centre names and contacts when published. General contacts added from the OncoDots directory are labelled separately. A “recruiting” status does not guarantee that a site is still accepting patients on the day you check, because the registry may lag behind the situation at the hospital. For any decision, consult the official record and discuss it with your doctor.